Q32 Bio (QTTB) Net Income towards Common Stockholders (2017 - 2026)

Q32 Bio's Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at -$7.6 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 31.02% year-over-year to -$7.6 million in Q1 2026; TTM through Mar 2026 was $3.5 million, a 128.51% increase from a year earlier, with the FY2025 full-year figure at $29821.0, up 162.47% from the prior year.
• Net Income towards Common Stockholders fell to -$7.6 million in Q1 2026 per QTTB's latest filing, from $27.9 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $92.7 million in Q1 2022 and bottomed at -$34.6 million in Q4 2022.
• The 5-year median for Net Income towards Common Stockholders is -$7.6 million (2026), against an average of -$536273.8.
• Across the five-year window, Net Income towards Common Stockholders soared 8738.96% in 2022 and slumped 1172.01% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$34.6 million in 2022, then surged by 177.04% to $26.6 million in 2023, then rose by 25.82% to $33.5 million in 2024, then slipped by 16.59% to $27.9 million in 2025, then sank by 127.23% to -$7.6 million in 2026.
• Per Business Quant, the three latest QTTB Net Income towards Common Stockholders figures stand at -$7.6 million (Q1 2026), $27.9 million (Q4 2025), and -$7.4 million (Q3 2025).